voriconazole
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Invasive Fungal Infections
Conditions
Invasive Fungal Infections
Trial Timeline
Jan 1, 2006 → Jun 1, 2007
NCT ID
NCT00288197About voriconazole
voriconazole is a approved stage product being developed by Pfizer for Invasive Fungal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00288197. Target conditions include Invasive Fungal Infections.
What happened to similar drugs?
9 of 20 similar drugs in Invasive Fungal Infections were approved
Approved (9) Terminated (2) Active (10)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (15)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01092832 | Phase 3 | Terminated |
| NCT00836875 | Phase 3 | Terminated |
| NCT00855101 | Phase 1 | Completed |
| NCT00721578 | Pre-clinical | Completed |
| NCT00556998 | Phase 2 | Completed |
| NCT00455364 | Approved | Terminated |
| NCT00300677 | Approved | Completed |
| NCT01660334 | Pre-clinical | Completed |
| NCT01151085 | Pre-clinical | Completed |
| NCT00288197 | Approved | Completed |
| NCT00159822 | Phase 2/3 | Completed |
| NCT00136968 | Phase 1 | Completed |
| NCT00143312 | Approved | Completed |
| NCT00174473 | Phase 1/2 | Completed |
| NCT00647907 | Approved | Completed |
Competing Products
20 competing products in Invasive Fungal Infections